Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Thursday morning,Benzinga reports. They currently have a $14.00 price objective on the stock.

Several other equities analysts have also recently commented on the stock. D. Boral Capital reissued a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, November 11th.

Coya Therapeutics Stock Performance

COYA opened at $7.00 on Thursday. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69. The stock’s 50 day moving average price is $5.87 and its 200 day moving average price is $6.40.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. On average, equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Insider Activity

In other Coya Therapeutics news, CEO Arun Swaminathan bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, with a total value of $36,700.00. Following the completion of the purchase, the chief executive officer now directly owns 5,000 shares in the company, valued at approximately $36,700. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders acquired 9,510 shares of company stock worth $69,615. Corporate insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in COYA. Renaissance Technologies LLC bought a new stake in shares of Coya Therapeutics during the 2nd quarter worth $101,000. GHP Investment Advisors Inc. purchased a new stake in shares of Coya Therapeutics during the third quarter valued at $169,000. Newbridge Financial Services Group Inc. acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at $401,000. Finally, Geode Capital Management LLC boosted its position in shares of Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the period. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.